Benefit of early treatment in inflammatory polyarthritis patients with anti-cyclic citrullinated peptide antibodies versus those without antibodies: Commentary

Tom Huizinga*, Peter Nigrovic, Eric Ruderman, Hendrik Schulze-Koops

*Corresponding author for this work

Research output: Contribution to journal › Comment/debate › peer-review

Fingerprint

Dive into the research topics of 'Benefit of early treatment in inflammatory polyarthritis patients with anti-cyclic citrullinated peptide antibodies versus those without antibodies: Commentary'. Together they form a unique fingerprint.